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Background:  The Mehran Bleeding Score (MBS), an integer risk score for Non-CABG Major Bleeding (MB) within 30 days from a multivariable 
logistic regression model based on 6 baseline measures (female sex, advanced age, elevated serum creatinine, white blood cell count, anemia, 
non-ST-segment elevation MI or ST-segment elevation acute MI, STEMI) and one treatment related variable (use of heparin - a glycoprotein IIb/
IIIa inhibitor rather than bivalirudin alone), has been demonstrated to be clinically useful for prediction of non-CABG-related major bleeding and 
subsequent 1-year mortality in patients with ACS that were studied in the ACUITY and HORIZONS-AMI trials.
We aim to validate the MBS in the setting of real-world patients undergoing primary PCI for STEMI for prediction of both in hospital MI, and short 
and one-year all-cause death.
Methods:  We assigned 1223 consecutive STEMI patients undergoing primary PCI to 4 risk category of MB according to MBS (low, moderate, high 
and very-high risk). We evaluated in hospital and 1-month MB, and all-cause-death after 6 months follow-up.
Results:  The incidence of MB within 30 days according to the Risk Score Category of MBS was 11.3% in very-high risk group, 2.9% in the high 
risk group and 1.2%, and 0.6% in the moderate and lower risk groups respectively (Pearson Chi-Square test < .0001). At multivariate analysis, the 
incidence of MB in each group was not correlated with 1-year mortality; in fact, the indipendent predictors of all-cause death were: left ventricle 
ejection fraction <30% at presentation (P<0.0001), mulivessel disease (P<0.001), and diabetes (P<0.033).
Conclusions:  MBS may be applied for identifies patients undergoing primary PCI at high risk of short-term MB, but it is unable to predict mortality 
in the setting of real-world population undergoing primary PCI for STEMI. Other factors besides bleeding contribute to poor otcome in such patients.
